Global Hemostasis Valve Market, By Type (Hemostasis Valve Y-Connectors, Double Y-Connector Hemostasis Valves, One-Handed Hemostasis Valves, Others), Application (Angiography, Angioplasty), End-User (Hospitals, Ambulatory Surgical Centers, Others) – Industry Trends and Forecast to 2030.
Hemostasis Valve Market Analysis and Size
According to the World Health Organization (WHO), CVDs kill nearly 17.9 million people yearly, accounting for approximately 31% of all deaths. Furthermore, more than 75% of CVD fatalities occur in low and middle-income countries. Furthermore, the WHO estimates that heart attacks and strokes account for 85% of all deaths. This is increasing the demand for angiography and angioplasty procedures, which in turn is increasing the demand for hemostasis valves. A hemostasis valve prevents blood reflux, while an angiography catheter is inserted into a vessel. However, FDA recalls for hemostasis valves are a major impediment to market growth.
Data Bridge Market Research analyses that the hemostasis valve market, which was USD 93.60 million in 2022, is expected to reach USD 150.09 million by 2030, at a CAGR of 6.08% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Hemostasis Valve Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Hemostasis Valve Y-Connectors, Double Y-Connector Hemostasis Valves, One-Handed Hemostasis Valves, Others), Application (Angiography, Angioplasty), End-User (Hospitals, Ambulatory Surgical Centers, Others)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
|
|
Market Players Covered
|
Abbott (U.S.), Thermo Fisher Scientific Inc. (U.S.), HORIBA Europe Holding (Japan), Medtronic (Ireland), Technidyne Corporation (U.S.), BD (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), NIHON KOHDEN CORPORATION (Japan), Haemonetics Corporation (U.S.), Beckman Coulter Inc. (U.S.), Chrono-log Corporation (U.S.), Sysmex Corporation (Japan), Siemens (Germany), Danaher (U.S.) and Grifols S.A. (Spain)
|
|
Market Opportunities
|
|
Market Definition
Hemostasis is a physiological process that aids in preventing and controlling bleeding. The procedure is divided into three steps: vascular spasm (vasoconstriction), platelet plug formation, and coagulation. Some inherited diseases, such as haemophilia, where blood does not clot properly due to a lack of blood-clotting proteins, necessitate using a hemostasis valve. This valve is a device to decrease the risk of thromboembolism during neuroendovascular procedures. These have increased and decreased the risk of air embolism and blood loss.
Global Hemostasis Valve Market Dynamics
Drivers
- Rise in haemophilia
Rising blood clotting diagnosis rates among patients, particularly those who are more prone to losing excess blood from the body during surgeries, are major factors driving the market growth. According to the National Haemophilia Foundation, approximately 400,000 people were affected by haemophilia in 2019, and approximately 75% of people worldwide continue to receive inadequate treatment or do not have access to treatment. As a result, the market's growth is positively influenced.
- Increase in demand for point-of-care testing system
Patients and clinicians are more likely to use point-of-care diagnostic tests, and rising patient awareness of POC processes is driving the market growth. Furthermore, one of the drivers is the efficient use of POC devices for diagnosis by minimally skilled professionals. Several private organizations, including the California Institute of Technology, Dartmouth College, and international organizations, also support POC development initiatives. For instance, to enhance professionals' diagnostic testing outside of clinical laboratories, the American Association for Clinical Chemistry developed a certification program in August 2018. As a result, the market is anticipated to increase profitably during the forecast period.
Opportunities
- Raising awareness about hemostasis
Raising awareness about hemostasis conditions is expected to improve diagnostic rates and preventive care management, significantly increasing testing volume. The advancement of technology has resulted in the introduction of many novel diagnostic systems and tests, such as the introduction of automated blood coagulation analyzers, which will provide a significant growth opportunity for this market in the coming years.
Restraints/Challenges
- Concerns about the risks associated with hemostasis valves
Infrastructure constraints in healthcare facilities and a lack of skilled professionals are expected to hamper hemostasis valve market growth. Concerns about the risks associated with hemostasis valves, such as air leakage, which can cause an air embolism, are expected to challenge the hemostasis valve market.
This hemostasis valve market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the hemostasis valve market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent developments
- In November 2020, Freudenberg Medical recently completed its global headquarters in Massachusetts and its new medical production facility in Beverly, Massachusetts, which will open.
- In May 2019, Argon Medical announced the acquisition of Mana-Tech, Ltd., its exclusive distributor in the United Kingdom. as well as Ireland This acquisition of Mana-Tech, Ltd. is expected to provide the company with significant opportunities to expand its presence in the United Kingdom, Ireland, and throughout Europe.
Global Hemostasis Valve Market Scope
The hemostasis valve market is segmented on the basis of type, application and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Type
- Hemostasis Valve Y-Connectors
- Double Y-Connector Hemostasis Valves
- One-Handed Hemostasis Valves
- Others
Application
- Angiography
- Angioplasty
End-User
- Hospitals
- Ambulatory Surgical Centers
- Others
Hemostasis Valve Market Regional Analysis/Insights
The hemostasis valve market is analysed and market size insights and trends are provided by country, type, application and end-user as referenced above.
The countries covered in the hemostasis valve market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the hemostasis valve market because of the increasing presence of key players, technological advancement and growing prevalence of blood disorder disease.
Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 because of the increasing prevalence of hemophilia in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The hemostasis valve market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for hemostasis valve market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the hemostasis valve market. The data is available for historic period 2011-2021.
Competitive Landscape and Hemostasis Valve Market Share Analysis
The hemostasis valve market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to hemostasis valve market.
Some of the major players operating in the hemostasis valve market are:
- Abbott (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- HORIBA Europe Holding (Japan)
- Medtronic (Ireland)
- Technidyne Corporation (U.S.)
- BD (U.S.)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- NIHON KOHDEN CORPORATION (Japan)
- Haemonetics Corporation (U.S.)
- Beckman Coulter Inc. (U.S.)
- Chrono-log Corporation (U.S.)
- Sysmex Corporation (Japan)
- Siemens (Germany)
- Danaher (U.S.)
- Grifols S.A. (Spain)
SKU-